Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)

Abstract

Background To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published “Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment” in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made. Methods A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020. Results The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines. Conclusion We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine.

Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis

“…Various factors can affect the results of NGS, including the process of library preparation, choice of assays, and the biomarker testing technique itself [ 89 , 90 , 91 ]. From the aspect of sample quality, two major factors are important to obtain successful results from NGS.…”

“…Furthermore, DNA extracted from FFPE tissues is generally damaged, and long-term storage may also affect the DNA quality. Thus, it is preferable to perform NGS in FFPE samples that have been prepared less than three years ahead of the sequencing [ 89 ].…”

A Brief Research on Cancer

“…You may use our A-to-Z List of Cancers or check the NCI website for updates on various types of cancer depending on their position in the body [10]. We also provide databases of information on cancers in children and youth, as well as cancers in young adults.…”

“…In multiple myeloma, cancerous plasma cells multiply in the bone marrow and crowd out healthy blood cells. Instead of producing beneficial antibodies, cancer cells contain defective proteins that can lead to complications [10].…”

Initial assessment of a cancer genomic profile test for patients with metastatic breast cancer: a retrospective study

“…The molecular tumor board consists of physicians specializing in cancer pharmacotherapy; physicians with expertise in genetic medicine; genetic counselors; pathologists; physicians with expertise in molecular genetics and cancer genomic medicine; and those with expertise in bioinformatics. The evidence levels for therapeutic e cacy were categorized as A to F, following the JSMO/JSCO/JCA guideline (10). The actionable gene mutations were de ned as following, predictive evidence level D and more (10) and high-tumor mutation burden (after approval of pembrolizumb by FDA).…”